ELIQUENT Expands with Truliant Acquisition

ELIQUENT Life Sciences, a portfolio company of GHO Capital Partners LLP, has announced its acquisition of Truliant Consulting, a firm recognized for its expertise in pharmacovigilance, risk management, and regulatory compliance. This strategic acquisition enhances ELIQUENT’s position as a leading provider of comprehensive support throughout the product lifecycle, with a specific focus on expanding its pharmacovigilance platform. The acquisition aligns with ELIQUENT's strategy of combining expert industry knowledge with advanced technology and scalable solutions. Truliant's integration will bolster ELIQUENT's capabilities in offering robust regulatory success strategies. The recent addition of Shelley Gandhi, a renowned figure in pharmacovigilance, to ELIQUENT’s team further underscores this commitment. This new collaboration promises to drive innovation and extend the range of solutions ELIQUENT can deliver, focusing on risk management, operational efficiency, compliance readiness, safety oversight, technology integration, and flexible support models.